Affordable Access

Publisher Website

Clinical Relevance: Cytokines in Alzheimer’s Disease

Elsevier Science & Technology
DOI: 10.1016/s1567-7443(07)10024-7
  • Medicine


Abstract Alzheimer’s disease (AD) is a complex interplay between various possible brain insults and the cytokine response resulting in a microlocalized inflammation in predictable areas of the central nervous system (CNS). The process of Alzheimer's is like ‘rheumatoid arthritis of the brain’. Progression of AD leads to a total body phenomenon, which leads to death in 8 years on average. Because the illness is multifaceted, treatment and prevention should be as well. Prevention may be possible through the use of daily oral antioxidants to reduce vulnerability to AD. Chronic use of cyclooxygenase (COX)-2 inhibitors could be supported with the onset of pre-Alzheimer’s forgetfulness. The use of sex steroids could be considered at about this time. With the onset of illness, anticholinesterase inhibitor is the principal therapy. Selective use of antidepressants should be considered as depression is so frequent in AD. Curiously, there appears to be a role for psychostimulants to treat the atypical depressions seen in AD patients while slowing the progress of AD.

There are no comments yet on this publication. Be the first to share your thoughts.


Seen <100 times

More articles like this

Clinical relevance on Alzheimer's disease endpoint...

on The journal of nutrition, heal... 2007

Cytokines and Alzheimer's disease.

on Immunology Today June 1992

Cytokines in Alzheimer's disease.

on Progress in Neuro-Psychopharma... 1991
More articles like this..